Ortho

Gozio Health Survey: Majority of Health Systems Recognize Value of Mobile Engagement Platforms, Yet 1 in 5 Lacks Offering

Retrieved on: 
Monday, July 18, 2022
Health Technology, Data Management, Other Health, Technology, Surgery, Apps, Applications, Managed Care, Hospitals, Baby, Maternity, Cardiology, Software, Consumer, Nursing, Health, Mobile, Wireless, Ortho, Thought, Research, Health information management, CEO, Cancer, Gozio Amaretto, Patient, LinkedIn, Safety, Wayfinding, Adoption, Twitter, Goal, Emergency department, Marketing, Organization, Health, EMR, Mobile phone

Whats more, 82% of health system executives plan to increase investment in patient-facing mobile technology over the next three years.

Key Points: 
  • Whats more, 82% of health system executives plan to increase investment in patient-facing mobile technology over the next three years.
  • Key findings from the survey include:
    Consumer-facing mobile apps are a critical component of health systems digital strategy.
  • More than half of health system executives ranked the importance of a mobile app as a 9 or a 10.
  • The research was conducted to determine health systems top challenges around mobile app engagement and digital health success.

Insights on the Rotator Cuff Injury Treatment Global Market to 2027 - Featuring 3S Ortho, Anika Therapeutics, Arthrex and BREG Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Health, General Health, Olympus Corporation, Decision-making, Acquisition, DJO, USD, Treatment, Ortho, Strategic management, Value, R, Business Growth Fund, COVID-19, Customer support, Growth, Smith & Nephew, LLC, Investment, Certification, CAGR, Stryker Corporation, Use, Rotator cuff, A, Agriculture, Retail, Medical device, Physical therapy, Injury, Medication

What are the inhibiting factors and impact of COVID-19 shaping the Global Rotator Cuff Injury Treatment Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Rotator Cuff Injury Treatment Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Rotator Cuff Injury Treatment Market?
  • What is the market share of the leading vendors in the Global Rotator Cuff Injury Treatment Market?
  • What modes and strategic moves are considered suitable for entering the Global Rotator Cuff Injury Treatment Market?

Physician Growth Partners advises Orthopaedic Specialists of Austin in transaction with Growth Ortho

Retrieved on: 
Wednesday, June 22, 2022
Development, Culture, The Company, Ortho, Leadership, PGP, OSA, Growth, Appetite, Physician, Acquisition, PE, Partnership, GLOBE, Security (finance), Medicine, Sales, Trivest

CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) -- Physician Growth Partners ("PGP") is pleased to have advised Orthopaedic Specialists of Austin ("OSA" or the "Company"), in its recent transaction with Growth Ortho, a private equity-backed orthopaedic platform and portfolio company of Florida-based Trivest Partners.

Key Points: 
  • CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) -- Physician Growth Partners ("PGP") is pleased to have advised Orthopaedic Specialists of Austin ("OSA" or the "Company"), in its recent transaction with Growth Ortho, a private equity-backed orthopaedic platform and portfolio company of Florida-based Trivest Partners.
  • OSA is led by seven shareholders and a veteran practice administrator who have developed since 2004 the premier, sub-specialty-focused orthopaedic practice in the Austin area.
  • Michael Kroin, Managing Partner at Physician Growth Partners, added, "It was an honor representing the OSA shareholder team in their transaction with Growth Ortho.
  • Physician Growth Partners is one of the most active national healthcare advisory firms dedicated to representing physician platforms in transactions with private equity.

Aligned Orthopedic Partners and PatientIQ Enter Partnership to Provide Top-Tier Care Across the DC Region

Retrieved on: 
Wednesday, June 15, 2022
Industry, Registry, Intelligence, CEO, Ortho, Research, Hospital, EHR, Physician, MD, Partnership, Patient, Collection, Organization, Medicine, Medical imaging

WASHINGTON, June 15, 2022 /PRNewswire-PRWeb/ -- Aligned Orthopedic Partners (Aligned Ortho), a leading multi-subspecialty orthopedic practice in the greater Washington, D.C. area, has entered into a strategic partnership with PatientIQ, a best-in-class technology company that collects, measures, and analyzes patient outcomes data to improve clinical and operational performance. The partnership will enable Aligned Ortho to derive actionable insights from its patient outcomes data at scale to ensure top-tier care across its locations.

Key Points: 
  • The partnership will enable Aligned Ortho to derive actionable insights from its patient outcomes data at scale to ensure top-tier care across its locations.
  • Aligned Ortho is composed of the orthopedic provider organizations known as OrthoBethesda , Shady Grove Orthopedics, and Washington Orthopaedics & Sports Medicine .
  • "Most provider organizations claim to provide top-tier clinical care, but very few can prove it," said Matthew Gitelis, CEO, PatientIQ.
  • Aligned Orthopedic Partners is a leading provider of comprehensive musculoskeletal care to patients in the greater Washington, D.C. market.

Greystone Provides $12.75 Million in Acquisition Financing for Texas Skilled Nursing Facility

Retrieved on: 
Monday, June 13, 2022
Goal, Ortho, FHA, Stroke, LLC, Fannie Mae, Â, Growth, GLOBE, Acquisition, Freddie Mac, Cardiac rehabilitation, HUD, Real estate

NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Greystone , a leading national commercial real estate finance company, has provided $12,750,000 in bridge financing for the acquisition of Highland Meadows Health & Rehab, a 120-bed skilled nursing facility in Rockwall, Texas.

Key Points: 
  • NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Greystone , a leading national commercial real estate finance company, has provided $12,750,000 in bridge financing for the acquisition of Highland Meadows Health & Rehab, a 120-bed skilled nursing facility in Rockwall, Texas.
  • The $12.75 million in non-recourse bridge financing from Greystone features a 24-month term with one 12-month extension option and is interest-only.
  • Greystone has already begun working with the new owner to follow a path in exiting the interim financing with a long-term HUD-insured permanent loan.
  • Loans are offered through Greystone Servicing Company LLC, Greystone Funding Company LLC and/or other Greystone affiliates.

QuidelOrtho Formed by the Completion of Transaction Combining Quidel and Ortho Clinical Diagnostics

Retrieved on: 
Friday, May 27, 2022
Technology, Medical Devices, Infectious Diseases, Other Health, Biotechnology, General Health, Health, Data Management, Science, Other Science, Knowledge, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Nasdaq, Webcast, Patient, NASDAQ, IVD, Health, Automation, Nature, Commission, Immunoassay, Transfusion medicine, Conference, Interest, Terminology, Central Time Zone, Ortho Clinical Diagnostics, Security (finance), Management, Medical device, Risk management, Quidel Corporation, Ortho

QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho) announced completion of the transaction combining Quidel Corporation (Quidel) and Ortho Clinical Diagnostics Holdings plc (Ortho), creating QuidelOrtho, a leading in vitro diagnostics company.

Key Points: 
  • QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho) announced completion of the transaction combining Quidel Corporation (Quidel) and Ortho Clinical Diagnostics Holdings plc (Ortho), creating QuidelOrtho, a leading in vitro diagnostics company.
  • Under the terms of the agreement governing the transaction, former Ortho shareholders received $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share.
  • Former Quidel stockholders received one share of QuidelOrtho common stock for each share of Quidel common stock.
  • The QuidelOrtho board is composed of 8 former Quidel board members and 4 former Ortho board members.

Quidel and Ortho Announce Expected Closing of Ortho Transaction

Retrieved on: 
Thursday, May 26, 2022
Form, Registrar of Companies, Food, U.S. Securities and Exchange Commission, SVC, Antibody, UK, Blood, YouTube, Terminology, Private Securities Litigation Reform Act, Twitter, Laboratory, JOINT, City Code on Takeovers and Mergers, Mergers and acquisitions, Nature, COVID-19, Failure, SAN, Food and Drug Administration, Facebook, Youth justice in England and Wales, Attention, Hospital, GLOBE, Part, Infection, Health, IVD, FDA, Efficiency, Communication, THE, LinkedIn, HIV, Security (finance), Telephone, Takeover, Patient, NASDAQ, High Court, Drug Master File, Hepatitis C, Commission, TO, Linear code, Medical device, Vaccine, Risk management, Quidel Corporation, Ortho, Nasdaq, Topco

Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq.

Key Points: 
  • Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq.
  • Under the terms of the agreement governing the transaction, Ortho shareholders will receive $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share.
  • Quidel stockholders will receive one share of QuidelOrtho common stock for each share of Quidel common stock.
  • Each of Quidel and Ortho commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Quidel and Ortho, respectively, on or about April 11, 2022.

Quidel and Ortho Announce Expected Closing of Ortho Transaction

Retrieved on: 
Thursday, May 26, 2022
Technology, Research, Infectious Diseases, Clinical Trials, Health, Pharmaceutical, General Health, Data Management, Science, Form, Registrar of Companies, Food, U.S. Securities and Exchange Commission, SVC, Antibody, UK, Blood, YouTube, Terminology, Private Securities Litigation Reform Act, Twitter, Laboratory, JOINT, City Code on Takeovers and Mergers, Mergers and acquisitions, Nature, COVID-19, Failure, Food and Drug Administration, Facebook, Youth justice in England and Wales, Attention, Hospital, Part, Infection, Health, IVD, FDA, Efficiency, Communication, THE, LinkedIn, HIV, Security (finance), Telephone, Takeover, Corporation, Patient, NASDAQ, High Court, Drug Master File, Hepatitis C, Commission, TO, Linear code, Medical device, Vaccine, Risk management, Quidel Corporation, Ortho, Nasdaq, Topco

Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq.

Key Points: 
  • Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq.
  • Under the terms of the agreement governing the transaction, Ortho shareholders will receive $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share.
  • Quidel stockholders will receive one share of QuidelOrtho common stock for each share of Quidel common stock.
  • Each of Quidel and Ortho commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Quidel and Ortho, respectively, on or about April 11, 2022.

Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction

Retrieved on: 
Monday, May 16, 2022
Food, U.S. Securities and Exchange Commission, Antibody, Press release, Lists of disasters, Blood, YouTube, Securities Act of 1933, England, Twitter, Director, Laboratory, United, Certification, COVID-19, Failure, Food and Drug Administration, Facebook, Youth justice in England and Wales, Government, Board, Hospital, Acquisition, Growth, GLOBE, Company, Insurance, IVD, Health, Defense, Ownership, Efficiency, Organization, LinkedIn, Securities Exchange Act of 1934, HIV, Security (finance), Data management, Risk, BCA, Nasdaq, Patient, NASDAQ, High Court, Hepatitis C, Privacy, Intellectual property, Forward-looking statement, Compliance, Safety, Union, Board of directors, Sumathi Best Television Current Reporting Award, Quidel Corporation, Ortho

RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (Ortho or the Company), one of the worlds largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ: QDEL) (Quidel) pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto (the BCA).

Key Points: 
  • RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (Ortho or the Company), one of the worlds largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ: QDEL) (Quidel) pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto (the BCA).
  • We have greatly appreciated the opportunity to engage in a thoughtful and constructive dialogue with our shareholders throughout this process.
  • We believe the combination of Quidel and Ortho will be well-positioned to accelerate growth through a broader commercial channel, stronger R&D capabilities, enhanced brand recognition, and wider overall reach by combining Quidel and Orthos complementary, world-class products.
  • Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies.

Quidel Announces Stockholder Approval of Ortho Acquisition and Business Combination

Retrieved on: 
Monday, May 16, 2022
Technology, Medical Devices, Infectious Diseases, Other Technology, Biotechnology, Other Health, Health, General Health, Data Management, Part, Telephone, Form, Takeover, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, SVC, Corporation, Nasdaq, City Code on Takeovers and Mergers, Infection, Patient, Topco, High Court, SEC filing, Mergers and acquisitions, Nature, Commission, COVID-19, Failure, FDA, UK, TO, Youth justice in England and Wales, Court, Attention, Communication, Terminology, THE, Linear code, England, Acquisition, Security (finance), JOINT, Annual report, Risk management, Quidel Corporation, Ortho

Quidel Corporation (Nasdaq: QDEL) (Quidel), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc (Ortho) by Quidel and subsequent business combination were approved by Quidels stockholders at Quidels Special Meeting on May 16, 2022.

Key Points: 
  • Quidel Corporation (Nasdaq: QDEL) (Quidel), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc (Ortho) by Quidel and subsequent business combination were approved by Quidels stockholders at Quidels Special Meeting on May 16, 2022.
  • Under the terms of the agreement by which Quidel will acquire Ortho, Ortho shareholders will receive $7.14 in cash and 0.1055 shares of the combined company common stock for each Ortho common share.
  • In connection with the proposed business combination transaction among Quidel, Ortho and Coronado Topco, Inc. (Topco), Topco has filed a registration statement on Form S-4 (File No.
  • Each of Quidel and Ortho commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Quidel and Ortho, respectively, on or about April 11, 2022.